KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Biogen (BIIB) R&D In Process (2017 - 2021)

Historic R&D In Process for Biogen (BIIB) over the last 5 years, with Q2 2021 value amounting to $18.0 million.

  • Biogen's R&D In Process changed N/A to $18.0 million in Q2 2021 from the same period last year, while for Jun 2022 it was $18.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $18.0 million for FY2021, which is 7600.0% down from last year.
  • Biogen's R&D In Process amounted to $18.0 million in Q2 2021.
  • Biogen's R&D In Process' 5-year high stood at $120.0 million during Q2 2017, with a 5-year trough of $10.0 million in Q1 2018.
  • For the 4-year period, Biogen's R&D In Process averaged around $54.2 million, with its median value being $51.2 million (2018).
  • The largest annual percentage gain for Biogen's R&D In Process in the last 5 years was 3750.0% (2018), contrasted with its biggest fall of 3750.0% (2018).
  • Quarter analysis of 4 years shows Biogen's R&D In Process stood at $120.0 million in 2017, then crashed by 77.08% to $27.5 million in 2018, then soared by 172.73% to $75.0 million in 2020, then tumbled by 76.0% to $18.0 million in 2021.
  • Its last three reported values are $18.0 million in Q2 2021, $75.0 million for Q1 2020, and $27.5 million during Q3 2018.